Results 41 to 50 of about 13,763 (191)

Multifunctional polycaprolactone‐based composite fibers with icariin and glutathione for effective repair of critical‐sized bone defects

BMEMat, EarlyView.
A multifunctional PCL‐based scaffold co‐delivering Icariin and Glutathione synergistically enhances osteogenesis, angiogenesis, and oxidative stress resistance, achieving near‐complete repair of critical‐sized bone defects in vivo. This cell‐free platform represents a promising strategy for accelerated bone regeneration.
Abdurohman Mengesha Yessuf, Yaqi Zhang, Bharat Prasad Sharma, Yake Wang, Tibebu Shiferaw Kassa, Abdul Qadir, Ye Jinqiu, Mohamedazeem M. Mohideen, Ahmed M. Salama, Weiguo Wang, Qidong Zhang, Yong Liu   +11 more
wiley   +1 more source

Management of severe bone loss in patients at risk of medication‐related osteonecrosis of the jaw with microsurgery and guided bone regeneration: A case study

Clinical Advances in Periodontics, EarlyView.
Abstract Background Medication‐related osteonecrosis of the jaw (MRONJ) is a challenging complication associated with antiresorptive medications. Its exact pathophysiology remains unclear, but dental extractions and infections are known triggers, complicating prevention, and treatment.
Pedro Franco Ferreira, José Maurício Paradella de Camargo, Lara Maria Alencar Ramos Innocentini, Ana Carolina Fragoso Motta   +3 more
wiley   +1 more source

Effect of Vitamin K and Alendronate Combination Treatment on Bone Mineral Density of Postmenopausal Osteoporosis Patients: A Pilot Study [PDF]

Patient Safety and Quality Improvement Journal, 2016
Introduction: Osteoporosis is a common problem in postmenopausal women. Numerous studies investigated the effects of vitamin K on bone health, which yielded conflicting results.
Mohammad Hassan Jokar, Zahra Mirfeizi, Habiballah Esmaili, Mohsen Khamoshi   +3 more
doaj  

Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Recent advances in cancer screening, diagnosis, and treatment have greatly improved survival rates among women with gynecologic cancers. More survivors now live long enough to experience treatment‐related menopause. Vasomotor symptoms, genitourinary syndrome of menopause, sexual dysfunction, sleep issues, and long‐term risks from estrogen ...
Agnaldo Lopes da Silva‐Filho, Suvarna Khadilkar, Hema Divakar, Chiara Benedetto, Andrea R. Genazzani, Diana Ramos, Elizabete Argale, Enrique Herrera, Martha Hickey   +8 more
wiley   +1 more source

Supplement With Calcium or Alendronate Suppresses Osteopenia Due to Long Term Rabeprazole Treatment in Female Mice: Influence on Bone TRAP and Osteopontin Levels

Frontiers in Pharmacology, 2020
Background and PurposeRabeprazole, a proton pump inhibitor (PPIs) is much endorsed to patients with increased gastric acidity. PPIs were accused to have osteoporotic effects on patients who chronically use them. The point of the current investigation was
Aly A.M. Shaalan, Aly A.M. Shaalan, Mohamed El-Sherbiny, Mohamed El-Sherbiny, Taghrid B. El-Abaseri, Mohamed Z. Shoaeir, Tarek M. Abdel-Aziz, Magda I. Mohamed, Sawsan A. Zaitone, Sawsan A. Zaitone, Hala M. F. Mohammad, Hala M. F. Mohammad   +11 more
doaj   +1 more source

Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Fracture risk is increased in Parkinson's yet this risk is often not addressed. Objectives Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.
Katie C. Naylor, Emily J. Henderson, Emma Tenison   +2 more
wiley   +1 more source

Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study

BMC Musculoskeletal Disorders, 2010
Background A rise in gastrointestinal (GI) adverse events (AEs) and a decline in bone mineral density (BMD) was observed in patients previously tolerant to brand alendronate shortly after generic versions were introduced in July 2005 to the Canadian ...
Papaioannou Alexandra, Grima Daniel T, Airia Parisa, Ioannidis George, Adachi Jonathan D   +4 more
doaj   +1 more source

The mediating role of genes in the influence of intestinal flora on type 2 diabetes and the screening of diagnostic markers

Journal of Diabetes Investigation, EarlyView.
Using Mendelian randomization, TWAS/eQTL analysis, machine learning, and single‐cell RNA sequencing, this study identified gut microbiota taxa causally linked to type 2 diabetes, candidate mediator genes, and diagnostic markers (BEND7, BLVRA, C1orf85, and LAMC1).
Yu‐yang Chen, Yi‐fan Shi, Xin‐yue Zhang, Jing‐yue Zhang, Shi‐mao Zhang, Heng‐xia Zhao, De‐liang Liu   +6 more
wiley   +1 more source

Alendronate Sodium as Enteric Coated Solid Lipid Nanoparticles; Preparation, Optimization, and In Vivo Evaluation to Enhance Its Oral Bioavailability. [PDF]

PLoS ONE, 2016
Treatment of osteoporosis with alendronate sodium has several challenges. The first challenge is the low bioavailability. The second main challenge is side effects, which include oesophageal ulceration.
Khaled Mohamed Hosny
doaj   +1 more source

Harnessing the Therapeutic Potential of Cell Secretomes and Extracellular Vesicles for Craniofacial Regenerative Applications

Journal of Periodontal Research, EarlyView.
The scoping review summarizes the current preclinical and clinical evidence for the use of “cell‐free” therapies in craniofacial (periodontal, bone and soft‐tissue) regeneration. It also aims to highlight key challenges and strategies towards the clinical translation of these therapies.
Siddharth Shanbhag, Magdalena Mayol, Danijel Domic, Madhusudhan Reddy Bobbili, Johannes Grillari, Mariano Sanz, Reinhard Gruber   +6 more
wiley   +1 more source